Grace Therapeutics (NASDAQ:GRCE) Trading Up 1.9% - Should You Buy?

Key Points

• Shares rose 1.9% to a last trade of $4.36 (intraday high $4.75) on volume of ~1,083,486 shares, up 28% versus the average daily volume of 844,764.
• Analysts are mixed—one Buy and one Sell—leaving an average rating of Hold$12.00.
• Grace is a clinical-stage biotech with a market cap of $67.45 million; it reported ($0.14) EPS last quarter (missing estimates) and analysts project roughly -1.06 EPS for the year while advancing gene/protein programs for rare genetic and lysosomal storage disorders.

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report)'s share price was up 1.9% during trading on Wednesday . The company traded as high as $4.75 and last traded at $4.36. Approximately 1,083,486 shares changed hands during trading, an increase of 28% from the average daily volume of 844,764 shares. The stock had previously closed at $4.28.

Analysts Set New Price Targets

A number of equities analysts have recently commented on GRCE shares. Wall Street Zen raised Grace Therapeutics to a "hold" rating in a report on Friday, January 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Grace Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Grace Therapeutics presently has an average rating of "Hold" and a consensus price target of $12.00.

Grace Therapeutics Trading Up 1.9%

The firm has a market cap of $67.45 million, a P/E ratio of -10.90 and a beta of 0.68. The business has a 50-day moving average of $4.09 and a two-hundred day moving average of $3.58.

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.05). As a group, equities analysts expect that Grace Therapeutics, Inc. will post -1.06 EPS for the current year.

Institutional Investors Weigh In On Grace Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GRCE. SeaCrest Wealth Management LLC bought a new stake in Grace Therapeutics during the 3rd quarter worth $42,000. ADAR1 Capital Management LLC grew its position in shares of Grace Therapeutics by 98.4% in the 3rd quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company's stock valued at $1,043,000 after buying an additional 173,823 shares during the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of Grace Therapeutics in the 4th quarter valued at about $39,000. Cerity Partners LLC bought a new stake in shares of Grace Therapeutics in the 4th quarter valued at about $1,463,000. Finally, Renaissance Technologies LLC grew its position in shares of Grace Therapeutics by 53.5% in the 4th quarter. Renaissance Technologies LLC now owns 129,781 shares of the company's stock valued at $449,000 after buying an additional 45,220 shares during the last quarter. Institutional investors own 6.08% of the company's stock.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc NASDAQ: GRCE is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company's pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.